
Rallybio Corp (RLYB) Stock Forecast & Price Target
Rallybio Corp (RLYB) Analyst Ratings
Bulls say
Rallybio Corp's RLYB212 has demonstrated promising Phase 1b proof-of-concept data, indicating its potential to effectively prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a severe condition lacking FDA-approved treatment options. The recent dosing of the first pregnant woman at high risk for FNAIT marks a significant milestone, underscoring the therapy's clinical potential and the company's commitment to addressing urgent healthcare needs. Additionally, the company has not modeled other pipeline programs, suggesting potential upside to its valuation that could further enhance its market position.
Bears say
Rallybio Corp reported a net loss of $0.25 per share, which underscores ongoing financial challenges facing the company as it seeks to advance its clinical programs. There are significant risks associated with potential delays in clinical trials for key pipeline candidates and the failure to generate positive clinical data, specifically for RLYB212 in fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116 in paroxysmal nocturnal hemoglobinuria (PNH). Additionally, partnership risks with entities such as Swedish Orphan Biovitrum AB, Exscientia PLC, and Sanofi S.A., along with long-term dilution risks, further contribute to a negative outlook for Rallybio's stock.
This aggregate rating is based on analysts' research of Rallybio Corp and is not a guaranteed prediction by Public.com or investment advice.
Rallybio Corp (RLYB) Analyst Forecast & Price Prediction
Start investing in Rallybio Corp (RLYB)
Order type
Buy in
Order amount
Est. shares
0 shares